Gennova Starts Enrolment For Human Trials Of HGCO19 Vaccine Candidate: Report

COVID-19 Vaccine India: The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19, developed by the biotechnology company.

Pune-based Gennova Biopharmaceuticals has initiated the enrolment of volunteers for Phase 1/2 clinical trials for its mRNA vaccine candidate HGCO19, said the Department of Biotechnology, which has provided seed funding for its development, on Tuesday. The DBT said it has approved additional funding towards clinical studies of India's first of its kind' mRNA-based COVID-19 vaccine, HGCO19, developed by the biotechnology company. The funding has been provided under the DBT's 'Mission COVID Suraksha -- The Indian COVID-19 Vaccine Development Mission'. It is being implemented by DBT's public sector undertaking Biotechnology Industry Research Assistance Council (BIRAC). "The DBT has been hand-holding Gennova right from the start and has facilitated establishing its mRNA-based next-generation vaccine manufacturing platform by providing seed funding for the development of HGCO19. Gennova, in collaboration with HDT Biotech Corporation, USA, has developed the COVID-19mRNA vaccine HGCO19, the DBT said.